Glyceroneogenesis Is the Dominant Pathway for Triglyceride Glycerol Synthesis *in Vivo* **in the Rat***

Received for publication, June 6, 2008, and in revised form, July 22, 2008 Published, JBC Papers in Press, July 28, 2008, DOI 10.1074/jbc.M804393200

Colleen K. Nye‡§1**, Richard W. Hanson**‡§**, and Satish C. Kalhan**§¶2

From the ‡ *Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio 44106,* ¶ *Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and* § *Departments of Gastroenterology and Pathobiology, Cleveland Clinic, Cleveland, Ohio 44195*

Triglyceride synthesis in mammalian tissues requires glycerol 3-phosphate as the source of triglyceride glycerol. In this study the relative contribution of glyceroneogenesis and glycolysis to triglyceride glycerol synthesis was quantified *in vivo* **in adipose tissue, skeletal muscle, and liver of the rat in response to a chow diet (controls), 48-h fast, and lipogenic (high sucrose) diet. The rate of glyceroneogenesis was quantified using the tritium ([³ H2]O) labeling of body water, and the contribution of glucose, via glycolysis, was determined using a [U-14C]glucose tracer. In epididymal and mesenteric adipose tissue of control rats, glyceroneogenesis accounted for 90% of triglyceride glycerol synthesis. Fasting for 48 h did not alter glyceroneogenesis in adipose tissue, whereas the contribution of glucose was negligible. In response to sucrose feeding, the synthesis of triglyceride glycerol via both glyceroneogenesis and glycolysis nearly doubled (***versus* **controls); however, glyceroneogenesis remained quantitatively higher as compared with the contribution of glucose. Enhancement of triglyceride-fatty acid cycling by epinephrine infusion resulted in a higher rate of glyceroneogenesis in adipose tissue, as compared with controls, whereas the contribution of glucose via glycolysis was not measurable. Glyceroneogenesis provided the majority of triglyceride glycerol in the gastrocnemius and soleus. In the liver the fractional contribution of glyceroneogenesis remained constant (60%) under all conditions and was higher than that of glucose. Thus, glyceroneogenesis, in contrast to glucose, via glycolysis, is quantitatively the predominant source of triglyceride glycerol in adipose tissue, skeletal muscle, and liver of the rat during fasting and high sucrose feeding.**

Triglyceride synthesis is critical for the accretion of fat and for the transport of lipids in the blood. In addition, triglyceride synthesis is an essential component of the triglyceride-fatty

acid (TG-FA)³ cycle, in which fatty acids released from adipose tissue following lipolysis are re-esterified back to triglyceride (1, 2). Glycerol 3-phosphate (G-3-P) and fatty acyl-CoAs are the substrates for the synthesis of triglycerides. G-3-P can be formed by phosphorylation of glycerol via glycerol kinase or by the reduction of dihydroxyacetone phosphate via G-3-P dehydrogenase. Dihydroxyacetone phosphate can be derived from either glucose or pyruvate. Glycerol kinase, although highly active in the liver, is present at low activity in adipose tissue and skeletal muscle (3, 4). Glucose is generally considered to be the major carbon source for the synthesis of G-3-P in white and brown adipose tissue, skeletal muscle, and liver. However, the relative quantitative contribution of glucose and pyruvate (glyceroneogenesis) has not been examined systematically *in vivo*.

Glyceroneogenesis, the *de novo* synthesis of G-3-P from precursors other than glucose and glycerol (*i.e.* pyruvate, lactate, alanine, and citric acid cycle anions) has long been suggested as a potential pathway for triglyceride glycerol formation in adipose tissue (5, 6). The cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C) (EC 4.1.1.32), which catalyzes the GTP-dependent decarboxylation of oxaloacetate to form phosphoenolpyruvate, is a key regulatory enzyme in glyceroneogenesis. Ablation of PEPCK-C expression in adipose tissue resulted in mice that have a reduced fat mass, with some of the animals displaying lipodystrophy (7); conversely, mice overexpressing PEPCK-C in their adipose tissue became obese (8) and were markedly insulin-resistant when fed a high fat diet (9). Because fasting causes an increase in pyruvate incorporation into G-3-P as well as an increase in PEPCK-C activity, glyceroneogenesis has been implicated in the enhanced TG-FA cycling associated with fasting. Furthermore, a diet high in carbohydrate decreases the activity of PEPCK-C in white adipose tissue (10); these changes are largely due to alterations in gene transcription (11). We hypothesized that after 48 h fast PEPCK-C activity would be increased, resulting in enhanced glyceroneogenesis in the adipose tissue, whereas a high carbohydrate, lipogenic diet would decrease PEPCK-C activity and lower flux over this pathway.

Considerable triglyceride is present in skeletal muscle as lipid droplets deposited within the muscle fibers. Increases in the intramyocellular triglyceride pool have been observed in

^{*} This work was supported, in whole or in part, by National Institutes of Health Grants DK-58620 and DK-25541 (to R. W. H.) and HD-11089 and HD-042154 (to S. C. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to

indicate this fact. ¹ A Trainee on the National Institutes of Health Metabolism Training Grant

DK-21859 at Case Western Reserve University School of Medicine. ² To whom correspondence should be addressed: Dept. of Pathobiology, Lerner Research Institute, 9500 Euclid Ave., NE40; Cleveland, OH 44195. Tel.: 216-444-3445; E-mail: satish.kalhan@case.edu.

³ The abbreviations used are: TG, triglyceride; FA, fatty acid; Ra, rate of appearance; G-3-P, glycerol 3-phosphate; PEPCK, phosphoenolpyruvate carboxykinase; SA, specific activity.

response to endurance training as well as in insulin-resistant states (12, 13). PEPCK-C is also expressed in low quantities in skeletal muscle, although its metabolic role in this tissue is not clear. Overexpression of PEPCK-C in the skeletal muscle of the mouse resulted in a marked increase in intramyocellular triglyceride levels (14). Guo and Jensen (15) reported that, whereas glucose and glycerol contributed equally to triglyceride glycerol synthesis in the gastrocnemius of 24-h-fasted rats, the majority of G-3-P was derived from what they termed the "indirect pathway," which originated from reactions further down the glycolytic pathway.

In the liver the pathways of gluconeogenesis and glyceroneogenesis share a common set of reactions (16), so that these pathways cannot be functionally separated. Data from *in vivo* studies in humans fasted overnight (17) and from human subjects with type 2 diabetes (18) indicated that glyceroneogenesis and not glucose metabolism via glycolysis was the predominant source of the triglyceride glycerol in the circulation. However, the extent of hepatic glyceroneogenesis during an extended fast and in lipogenic conditions has not been examined *in vivo*.

In the present study we have quantified the relative contribution of glyceroneogenesis and glycolysis to the synthesis of triglyceride glycerol *in vivo* in white adipose tissue, skeletal muscle, and in the liver of rats over a range of physiological perturbations, *i.e.* controls, a 48-h fast, and in a lipogenic state induced by dietary sucrose supplementation. We have also examined glyceroneogenesis in adipose tissue in response to enhanced TG-FA cycling induced by the infusion of epinephrine.

EXPERIMENTAL PROCEDURES

Animals-Male Sprague-Dawley rats weighing ~250-275 g with indwelling carotid artery and jugular vein catheters were obtained from Zivic-Miller Laboratories (Zelienople, PA).

3– 4 days before transfer of animals to our institution, PE50 catheters were inserted in the right jugular vein and left carotid artery under sterile conditions and under anesthesia. The catheters were tunneled subcutaneously, and the distal end of each catheter was sutured to the dorsum of the neck. The catheters were filled with an anticoagulant solution, capped, and secured on the top of the neck. Post-operatively the animals were given analgesics for pain (0.2 ml of Ketosen, 10 mg/ml) and were placed on *ad libitum* rat chow and water.

The animals were housed in the Animal Resource Facility of Case Western Reserve University under controlled temperature (22 \pm 1 °C) and light (on at 0600 h, off at 1800 h). All procedures involving the rats used in this study were reviewed and approved by the Institutional Animal Care and Use Committee and conformed to American Association for Accreditation of Laboratory Animal Care Guidelines. The animals were fed rat chow (Purina Mills Prolab RMH 1800; 21% protein, 14% fat, 65% carbohydrate) and water *ad libitum* and were provided with environmental enrichment (chew squares). After entry into the facility, the rats were allowed a minimum of 4 days to acclimate to the new surroundings before the study.

Glyceroneogenesis was quantified in four groups of animals: 1) controls (food was removed at 7 a.m. on the morning of the tracer isotope study; water was provided *ad libitum*), 2) fasting

FIGURE 1. **Isotopic tracer study protocol.** Rats were given 0.5 mCi of [³H₂]O at time 0 followed by a prime constant-rate infusion of [U-¹⁴C]qlucose (prime = 9 μ Ci/kg; constant infusion = 9 μ Ci/kg/h) for 7 h. Animals moved freely about their cages during the study. Blood samples were collected during the final hour of the infusion, and tissues of interest were harvested while the tracer infusion was continued.

(food was removed 48 h before the tracer study; water was provided *ad libitum*), 3) high carbohydrate diet (in addition to rat chow, the animals were given sucrose water $(20\% \text{ w/v})$ for 5 days); food was removed at 7 a.m., sucrose water was discontinued, and animals received glucose intravenously (15 mg/kg/ min, as a 10% solution) throughout the tracer study to maintain the lipogenic state), and 4) response to epinephrine infusion (food was removed at 7 a.m. on the day of the tracer study; water was provided *ad libitum*, and epinephrine (Hospira, Inc.; Lake Forest, IL) was infused (500 ng/kg/min) via the jugular vein catheter for 3 h).

Tracer Study Protocol (Fig. 1)—Rats were given an intraperitoneal injection of 0.5 mCi of $[^3H_2]O$ (1.0 mCi/ml). This was followed immediately by $[U^{-14}C]$ glucose tracer in an isotonic saline solution as a prime constant rate infusion (prime $= 9$ μ Ci/kg, constant rate infusion = 9 μ Ci/kg/h) via the jugular vein catheter for 7 h. The animals were unrestrained, awake, and moved freely in the cage during the experiment. Blood samples (0.2 ml) were drawn from the carotid artery at 6, 6.5, and 7 h, and plasma was separated. At 7 h, the rats were given an anesthetic dose of sodium pentobarbital (Abbott Laboratories) via the carotid artery catheter, and the tissues of interest (epididymal and mesenteric fat, gastrocnemius, and soleus muscles) were harvested while the tracer infusion was continued. Plasma and tissues were stored at -80 °C until further analyses.

Triglyceride Extraction and the Isolation of Glycerol and Fatty Acids—Triglycerides were extracted from the tissues and plasma using a modification of the method of Folch *et al.* (19). Briefly, adipose tissue was homogenized in 2:1 (v/v) chloroform-methanol, whereas the muscle was homogenized in saline using an IKA-ULTRA-TURRAX T 25 basic tissue blender. Plasma samples and tissue homogenates were incubated in 2:1 (v/v) chloroform-methanol for 48 h at 4 °C, then 4 mm MgCl₂ was added, and the solution was mixed thoroughly and centrifuged at 1000 \times g for 1 h. The aqueous supernatant was removed, taken to dryness, and further processed as described below. The organic infranatant containing the triglycerides was dried and saponified by the addition of ethanolic KOH (0.5 N) followed by incubation at 70 °C for 1 h. To convert the carboxylate salts to the free acids, the samples were acidified by the addition of 6 N HCl. Fatty acids were extracted with hexane (Fluka) and dried. The aqueous layer containing glycerol was

dried and reconstituted in a fixed volume, and the concentration of glycerol was determined fluorometrically (20).

Isolation of Plasma Metabolites—Plasma glucose, glycerol, and lactate were separated by ion-exchange chromatography (Bio-Rad AG 1-X8 hydrogen resin; AG 50W-X8 formate resin) (18). Glucose and glycerol, eluted in the neutral fraction, were further separated by liquid chromatography (Hewlett Packard Agilent 1100 Series HPLC with Agilent ChemStation software; Bio-Rad Aminex HPX-87P Carbohydrate Analysis Column, 300×7.8 mm; mobile phase 100% water, flow rate 0.6 ml/min, column temperature 80 °C). The eluates were dried and reconstituted in a fixed volume. The glucose concentration was determined enzymatically using the Beckman Glucose Analyzer by the glucose oxidase method. The concentrations of glycerol and lactate were determined enzymatically using a fluorometric assay (20, 21).

Measurements of Radioactivity—The radioactivity of ³ H in a 20 - μ l aliquot of plasma was measured to determine the specific activity (SA) of body water. An aliquot of glucose, glycerol, and lactate, isolated from plasma samples (see above), was used to measure the total ³H and ¹⁴C radioactivity of each metabolite. The ³H and ¹⁴C radioactivity present in fatty acids and glycerol isolated (from triglycerides) in plasma and tissues was also measured.

Radioactivity of C-1 and (C-1 + *C-3)*—The ¹⁴C and ³H radioactivity of the C-1 and $(C-1 + C-3)$ triglyceride glycerol carbons was determined after dimedon derivatization according to the method of Reeves (22). Briefly, glycerol samples were subjected to periodate oxidation, and the formaldehyde formed was precipitated as a dimedon derivative. Each glycerol sample was divided in half; one aliquot was taken directly through the dimedon derivatization procedure, and the other aliquot was phosphorylated using glycerol kinase, as described by Bederman *et al.* (23), to form G-3-P before the derivatization. Incubation of glycerol (or G-3-P) with periodic acid results in cleavage of vicinal diols. Phosphorylation of glycerol to form G-3-P prevents the cleavage of C-3 by periodate. Thus, radioactivity on $(C-1 + C-3)$ and $C-1$ -only can be determined from the same sample of triglyceride glycerol.

Activity of PEPCK-C—The activity of PEPCK-C was determined by the method of Ballard and Hanson (24) using adipose tissue isolated from 48-h fasted and sucrose-fed animals. The tissues were homogenized in 0.25 M sucrose containing 5 mM Tris-HCl at pH 7.4 and 1 mm dithiothreitol. The cytosolic fraction, prepared by centrifuging the homogenate at 30,000 \times *g* for 30 min at 4 °C, was used to assay for PEPCK-C activity.

Calculations—The rate of appearance (Ra) of glucose in the blood was calculated during the isotopic steady state using the tracer dilution technique (25): Ra $(\mu \text{mol/kg/min}) = I/SA$, where *I* is the rate of infusion of $[U^{-14}C]$ glucose tracer (dpm/ kg/min), and SA = specific activity of glucose (dpm/ μ mol).

The SA of pyruvate was calculated from that of plasma water assuming complete equilibrium between the hydrogens on plasma water and the hydrogens on C-3 of pyruvate (Fig. 2). Therefore, the SA of pyruvate $= 3 \times$ SA of body water, assuming all three hydrogens on C-3 of pyruvate are in complete equilibrium with body water (26, 27). SA of body water = $1.11 \times SA$

FIGURE 2. **The incorporation of ³ H into G-3-P from body water.** Hydrogens of C-3 of pyruvate become labeled through exchange with body water during transamination with alanine and keto-enol tautomerization as well as during the equilibrium of malate with fumarate so that both hydrogens of C-3 of phosphoenolpyruvate, which forms the C-3 of glyceraldehyde-3-P, will have the same SA as that of body water. Additional labeling occurs at the level of the triose phosphate pool when C-1 and C-2 acquire ³H directly from the body water. Thus, the ³H of C-1 and C-2 of G-3-P were derived from the triose phosphate pool. The ³H of C-3 of G-3-P were derived entirely from pyruvate. Hydrogens labeled with ³ H are highlighted in *red*.

of plasma. The measured SA of plasma was multiplied by 1.11 because water constitutes 90% of plasma.

The rate of gluconeogenesis was calculated by dividing the ³H SA of glucose with the estimated SA of the triose phosphate pool. The SA of the triose phosphate pool $= 4 \times S$ A of body water, as there are four hydrogens on each molecule of triose phosphate (dihydroxyacetone phosphate and glyceraldehyde-3-P) in equilibrium with body water (Fig. 2). It was assumed that all the hydrogens on the triose phosphate molecules are labeled to the same extent as body water (26, 27). The rate of glyceroneogenesis in the adipose tissue and skeletal muscle was calculated as follows: glyceroneogenesis (nmol/g/h) = $(^3$ H in triglyceride glycerol (dpm/g/h) \times 2/5)/(pyruvate SA (dpm/ μ mol) \times 2/3).

The ³H radioactivity of triglyceride glycerol was multiplied by 2/5 as only two hydrogens in the glycerol moiety are derived from pyruvate (Fig. 2). The SA of pyruvate was multiplied by 2/3 since only two hydrogens on C-3 of pyruvate are incorporated into triglyceride glycerol. The SA of ³H on C-1 and C-2 of triglyceride glycerol will be the same as that of body water because of complete equilibrium in the triose phosphate pool. In contrast, ³H on C-3 of triglyceride glycerol is derived from pyruvate.

The "total" (direct plus indirect via lactate) rate of the glycolytic contribution to triglyceride glycerol in adipose tissue and skeletal muscle was calculated as follows: total (direct plus indirect) incorporation of glucose into triglyceride glycerol (nmol/ g/h) = 2 × (¹⁴C radioactivity in triglyceride glycerol (dpm/g/ h))/(^{14}C SA of glucose (dpm/ μ mol)).

The data are expressed as 3 carbon eq by multiplying the results by 2. The "direct" contribution of glucose carbon to triglyceride glycerol was calculated by subtracting the contri-

TABLE 1

Glucose kinetics, gluconeogenesis, and source of plasma triglyceride glycerol

Values are the mean ± S.E. Conc., concentration in the plasma; GNG, contribution of gluconeogenesis to glucose Ra; GlyNG, contribution of glyceroneogenesis to plasma triglyceride; glycolysis, contribution of glucose to plasma triglyceride. Suc Sup Glc Inf, sucrose-supplemented animals infused with glucose during the tracer study.

		Glucose			Triglyceride			
	Conc.	Ra	GNG	Conc.	GlvNG	Glycolysis		
	mм	μ mol/kg/min		mm	%			
Control $(n = 5)$	8.6 ± 1.0	35.6 ± 4.3	28.5 ± 2.9	0.841 ± 0.07	57.6 ± 2.2	14.8 ± 1.9		
48 h fast $(n = 5)$	6.3 ± 0.6	17.7 ± 0.6^a	58.6 ± 1.6^b	0.844 ± 0.06	56.1 ± 6.7	10.6 ± 0.7		
Suc Sup + Glc Inf $(n = 5)$	9.8 ± 0.9			0.803 ± 0.06	59.3 ± 2.7	27.8 ± 5.6		

 $\frac{a}{b}p < 0.05$ *vs.* control.
 $\frac{b}{p}p < 0.01$ *vs.* control.

bution of lactate (glyceroneogenesis) from the total glucose carbon incorporated into triglyceride glycerol. The contribution of lactate was calculated by multiplying the ${}^{14}C$ SA of lactate with the estimated glyceroneogenic flux from pyruvate (corrected for the loss of 14 C in the citric acid cycle; dilution factor 2.2) (28). Additional studies using four animals showed that the SA of the $[14C]$ lactate pool reached steady state within 1 h of the start of the $[{}^{14}C]$ glucose infusion (data not shown).

Plasma triglyceride glycerol from glyceroneogenesis $(\%)$ = ⁽³H SA plasma triglyceride glycerol (dpm/ μ mol) \times 2/5)/(SA of pyruvate (dpm/ μ mol) \times 2/3). Both the SA of triglyceride glycerol and pyruvate were adjusted, as only two hydrogens on C-3 of pyruvate are incorporated into the glycerol moiety. Plasma triglyceride glycerol from glucose (%) = $100 \times$ (¹⁴C SA plasma triglyceride glycerol (dpm/ μ mol) x 2)/(¹⁴C SA glucose (dpm/ μ mol)). The SA of triglyceride glycerol was multiplied by 2 since two 3-carbon eq are formed from one molecule of glucose. The rate of lipogenesis was calculated as described by Katz and Rognstad (29).

Statistical Analysis—Values are expressed as the mean \pm S.E. Analysis of variance was used to examine the differences between the three dietary groups. Two-tailed Student's *t* test (assuming unequal variance) was used to assess differences between two dietary groups for each tissue and within the same dietary group between two adipose tissue depots (or two types of skeletal muscle).

RESULTS

Glucose Kinetics, Gluconeogenesis, and the Source of Plasma Triglyceride Glycerol—The mean plasma glucose concentration of control and 48-h-fasted animals was 8.6 and 6.3 mM, respectively (Table 1). The mean plasma glucose concentration (9.8 mM) of the rats supplemented with sucrose was not significantly different when compared with controls. The glucose Ra was significantly lower in 48-h-fasted animals $(17.7 \mu \text{mol/kg})$ min) when compared with controls $(35.6 \mu \text{mol/kg/min})$ (Table 1). In the sucrose-supplemented group, intravenous glucose infusion resulted in complete suppression of endogenous glucose production. The fractional contribution of gluconeogenesis to glucose Ra, estimated from the incorporation of $3H$ of body water into glucose, was significantly higher in 48-h-fasted animals (58.6%) compared with the control group (28.5%) (Table 1). The contribution of gluconeogenesis to glucose Ra in the sucrose-supplemented group could not be calculated, because endogenous glucose production was completely suppressed.

The plasma concentration of triglyceride were not different in the three groups (Table 1). The fraction of plasma triglyceride glycerol derived from glyceroneogenesis was $~60\%$ and not different among the three groups (Table 1). Approximately 15% of triglyceride glycerol was derived from glucose in the control group (Table 1). The contribution of glucose was lower in 48-h fasted rats $(\sim 11\%)$ and was higher in sucrose-supplemented animals (\sim 28%). Although sucrose supplementation resulted in a higher contribution of glucose to plasma triglyceride glycerol when compared with controls, the contribution of glucose was less than that of glyceroneogenesis (Table 1). However, the estimated contribution of glucose includes both the direct and indirect (via lactate) pathways. Therefore, the reported contribution of glucose to plasma triglyceride glycerol also includes the 14 C incorporated into plasma triglycerides via glyceroneogenesis (from $[$ ¹⁴C]lactate).

Glyceroneogenesis and Glycolysis as a Source of Triglyceride Glycerol in Adipose Tissue—There was no significant ($p =$ ns) difference in the triglyceride concentration in the adipose tissue of controls and 48-h-fasted animals. In the sucrose-supplemented animals, the concentration of triglyceride was significantly higher than controls (Table 2).

Glyceroneogenesis was quantified using ³H incorporation into triglyceride glycerol and is expressed as incorporation of pyruvate equivalents. The rate of glyceroneogenesis in the control animals was \sim 600 nmol/g/h in the epididymal adipose depot and \sim 800 nmol/g/h in the mesenteric depot (Table 2). Glyceroneogenesis did not change in response to fasting for 48 h. In contrast, sucrose-supplementation resulted in a significant increase in this pathway in both adipose tissue depots. Glyceroneogenesis was higher in mesenteric adipose tissue as compared with epididymal adipose tissue in all groups; however, a statistically significant difference was only observed in the sucrose-supplemented group (Table 2).

Total and direct glucose carbon incorporated into triglyceride glycerol are displayed in Table 2. 48-h fast caused a significantly lower incorporation of total glucose carbon into triglyceride glycerol as compared with controls. In contrast, sucrose supplementation resulted in a higher total contribution of glucose carbon to triglyceride glycerol (Table 2). The direct contribution of glucose to triglyceride glycerol was \sim 80 nmol/g/h in control animals in both adipose depots (Table 2). In the 48-hfasted animals the direct contribution of glucose via glycolysis was negligible. In contrast, sucrose supplementation resulted in a doubling of the direct contribution of glucose to triglyceride glycerol in both adipose tissue depots.

TABLE 2

The contribution of glyceroneogenesis and glycolysis to triglyceride glycerol synthesis in adipose tissue

Values are the mean \pm S.E.; range is indicated in parentheses. GlyNG, glyceroneogenesis; Suc Sup + Glc Inf, sucrose-supplemented animals infused with glucose during tracer study. Glyceroneogenesis was quantified using tritium, [3H2]O, incorporation into triglyceride glycerol and is expressed as nmol of pyruvate/g/h. The contribution
of glucose was quantified using [U-¹⁴C]glucose and Direct, incorporation of glucose into triglycerides via triosephosphate.

 $\frac{a}{p}$ p $<$ 0.05 *vs.* control.
b p $<$ 0.01 *vs.* control.

TABLE 3

14C and ³ H radioactivity and 14C/3 H ratio on C-1 and (C-1 C-3) of triglyceride glycerol in the mesenteric adipose tissue

The mean \pm S.E. is reported for the ¹⁴C/³H ratio. C-1 and C-1 + C-3 (along with their corresponding hydrogens) were cleaved from triglyceride glycerol using periodate oxidation. The dimedon derivative of the formaldehyde formed was prepared as described under "Experimental Procedures." 14 C and 3 H radioactivity was measured. Each row represents the values obtained from an individual rat of the sucrose supplemented group.

Animal	$C-1 + C-3$			$C-1$			
	$\rm{^{3}H}$	^{14}C	$^{14}C/{}^{3}H$	$\rm{^{3}H}$	^{14}C	$^{14}C/{}^{3}H^b$	
	dpm	dpm		dpm	dpm		
	1574	2948	1.87	1220	189	0.15	
2	1893	2482	1.31	1255	133	0.11	
3	1812	2593	1.43	1145	139	0.12	
4	1186	1925	1.62	496	174	0.35	
5	1099	1731	1.58	423	173	0.41	
Average			$1.56 \pm 0.095^{\circ}$			0.23 ± 0.063^b	

 $a^a p < 0.05.$
b $p < 0.01$ *vs.* (C-1 + C-3).

We confirmed the predominance of glyceroneogenesis, as compared with glycolysis, by examining the ${}^{14}C/{}^{3}H$ ratio on C-1 and $(C-1 + C-3)$ of triglyceride glycerol. C-1 and $(C-1 + C-3)$ C-3) of glycerol were cleaved by periodate oxidation, and the radioactivity of the dimedon derivative was measured. We examined the mesenteric adipose tissue of sucrose supplemented rats because glyceroneogenesis was highest in the adipose tissue of this group. As shown in Table 3, the ¹⁴C/³H ratio was high on $(C-1 + C-3)$ as compared with C-1 of triglyceride glycerol. A high ${}^{14}C/{}^{3}H$ ratio on C-3 (or C-1 + C-3) suggests a greater contribution of glyceroneogenesis relative to the direct contribution of glucose via glycolysis to triglyceride glycerol synthesis (Fig. 3).

Fatty Acid Synthesis in Adipose Tissue—The incorporation of 14C of glucose into fatty acids was negligible in 48-h-fasted animals and high in controls in both the epididymal and mesenteric adipose tissue (Table 4). Furthermore, fatty acid synthesis in the sucrose-supplemented group was significantly higher as compared with control animals in both adipose tissue depots examined.

PEPCK-C Activity in the Adipose Tissue—Maximal PEPCK-C activity (0.33 units/g tissue) was noted in mesenteric fat of 48-hfasted rats and was significantly higher than that of the sucrosesupplemented group (0.025 units/g of tissue) (Fig. 4). Similar qualitative changes were observed in the epididymal adipose depot (0.14 units/g tissue in 48-h-fasted rats and 0.020 units/g tissue in the sucrose supplemented group). PEPCK-C activity

CH,

CH₂

Pyruvate

 $CH₃$ [¹⁴C]Lactate

FIGURE 3. **The relative contribution of glyceroneogenesis and of glucose by the direct and indirect (via lactate) pathways and its impact on the
¹⁴C/³H ratio of C-1 and C-3 of triglyceride glycerol. The box represents the
labeling pattern of G-3-P derived from [¹⁴C]glucose, [³H]pyruvat** [¹⁴C]lactate. When G-3-P is formed from [¹⁴C]glucose, all the carbons of G-3-P
will be equally labeled with ¹⁴C. In contrast, ³H, as a result of equilibrium in the 14 C]lactate. When G-3-P is formed from $[14$ C]glucose, all the carbons of G-3-P triosephosphate pool (Fig. 2), will appear on C-1 and C-2 and not C-3. G-3-P
formed from pyruvate will not have any ¹⁴C label, whereas the hydrogens on C-1, C-2, and $C-3$ will be completely labeled with ${}^{3}H$. On a stoichiometric equivalent basis, G-3-P formed from 1 molecule of glucose and 2 molecules of
pyruvate will have a ¹⁴C/³H ratio on C-1 of 2 ¹⁴C/8 ³H = 0.25 and on C-3 of 2
¹⁴C/4 ³H = 0.5. ¹⁴C of glucose can also be incorporat tate. However, as a result of randomization and the exchange of label in the TCA cycle, [14C]lactate entering the triose phosphate pool will have less label on C-1 relative to C-2 and C-3. Therefore, as the contribution of recycled glucose (via lactate) to G-3-P increases, there will be an increase in the ¹⁴C/³H ratio on C-3 and a decrease of the ratio on C-1. Thus, a high glyceroneogenic flux, relative to glycolytic flux, will result in a high $\rm ^{14}C/^{3}H$ ratio on C-3 (or C-1 $+$ C-3) as compared with that on C-1. Carbons labeled with 14C are *highlighted* in *blue*, and hydrogens labeled with ³ H are *highlighted* in *red*. *PEP*, phosphoenolpyruvate.

TABLE 4

Incorporation of glucose into *de novo* **synthesized fatty acids in adipose tissue**

Values are nmol/g/h, mean \pm S.E. Fatty acids were obtained after hydrolysis of triglyceride isolated from epididymal and mesenteric adipose tissue depots as described under "Experimental Procedures." The contribution of glucose carbon to the *de novo* synthesis of fatty acids was quantified during a prime constant-rate infusion of $[U^{-14}C]$ glucose. ND, non-detected; Suc Sup + Glc Inf, sucrose supplemented animals infused with glucose during tracer study.

 $a_p < 0.05$ *vs.* control.

was significantly higher in mesenteric fat *versus* epididymal fat of 48-h-fasted animals.

Response to Enhanced TG-FA Cycling by Epinephrine—Epinephrine infusion elevated the concentration of glucose in the plasma and enhanced the rate of lipolysis, as indicated by the increase in the concentration of free glycerol in the plasma (data not shown). In the control rats infused with saline, there was no change in the plasma glucose and glycerol concentrations.

Infusion of epinephrine caused a significant increase in glyceroneogenesis in epididymal adipose tissue (Table 5). Similarly, glyceroneogenesis in mesenteric adipose tissue was significantly higher in the epinephrine-infused rats (978 nmol/g/h) as compared with the control animals (479 nmol/g/h). Total glucose carbon incorporated into adipose tissue triglyceride glyc-

FIGURE 4. **The activity of PEPCK-C in adipose tissue.** Epididymal and mesenteric adipose tissue was collected from 48-h-fasted animals (*gray bars*) and from animals maintained on a sucrose supplemented diet and infused with glucose (*black bars*). The activity of PEPCK-C was determined in these tissues as described under "Experimental Procedures" and is expressed as the mean \pm S.E. for three rats. A unit of activity is defined as 1 μ mol of substrate converted to product/min/g tissue at 37 °C. *, $p < 0.05$; **, $p < 0.01$ versus 48 h fast.

erol was higher in rats infused with epinephrine when compared with controls (Table 5). However, after accounting for the contribution via lactate to triglyceride glycerol, the direct contribution of glucose via glycolysis was negligible in both depots (Table 5).

The Relative Contribution of Glyceroneogenesis and Glucose to Triglyceride Glycerol Synthesis in Skeletal Muscle—The concentration of triglyceride in the gastrocnemius and soleus muscles were not different among the three groups (Table 6). Glyceroneogenesis was quantifiable in both gastrocnemius and soleus*in vivo* and was not different in the two muscle types. The rate of glyceroneogenesis in the control animals was \sim 75 nmol/ g/h (Table 6). Sucrose supplementation resulted in a significant increase in glyceroneogenesis in the gastrocnemius only.

Total glucose carbon incorporated into triglyceride glycerol was \sim 20 nmol/g/h in the gastrocnemius and soleus of control rats (Table 6). Fasting for 48 h did not change the total glucose carbon incorporated into triglyceride glycerol in the skeletal muscle. In response to sucrose supplementation, a significant increase in total glucose incorporated into triglyceride glycerol was seen only in the soleus. After accounting for the contribution of lactate to triglyceride glycerol, the direct synthesis of triglyceride glycerol from glucose via glycolysis was negligible in both the gastrocnemius and soleus from all three groups of animals (Table 6).

DISCUSSION

In the present study we have examined the relative contribution of glyceroneogenesis and glucose via glycolysis to triglyceride glycerol synthesis in the rat. Our data show that glyceroneogenesis is quantitatively the predominant pathway for triglyceride glycerol synthesis in white adipose tissue, skeletal muscle, and liver during extended fasting as well as during peri-

TABLE 5

The effect of epinephrine infusion on the contribution of glyceroneogenesis and glycolysis to triglyceride glycerol in the adipose tissue

Values are the mean ± S.E.; range is indicated in parentheses. GlyNG, glyceroneogenesis, *Epi Inf*, epinephrine infusion. Glyceroneogenesis was quantified using tritium,
[³H₂]O, incorporation into triglyceride glycerol as three carbon equivalents. Total, includes carbon coming directly from glucose plus indirectly via [¹⁴C]lactate. Direct, incorporation of glucose into triglycerides via triosephosphate.

 $a_p < 0.05$ *vs.* control.

TABLE 6

The contribution of glyceroneogenesis and glucose to triglyceride glycerol synthesis in skeletal muscle

Values are the mean \pm S.E.; range is indicated in parentheses. GlyNG, glyceroneogenesis. Suc Sup + Glc Inf, sucrose-supplemented animals infused with glucose during tracer study. Glyceroneogenesis was quantified using tritium, [3H,]O, incorporation into triglyceride glycerol and is expressed as nmol of pyruvate/g/h. The contribution
of glucose was quantified using [U-¹⁴C]glucose and Direct, incorporation of glucose into triglycerides via triosephosphate.

 $^{a}p < 0.05$.

ods of glucose availability. Surprisingly, the highest rates of glyceroneogenesis in adipose tissue were observed in sucrosesupplemented animals, when fatty acid synthesis and triglyceride deposition were high.

We used tritium ($[^{3}H_{2}]$ O) labeling of body water in combination with $[U^{-14}C]$ glucose to quantify the relative contributions of glyceroneogenesis and glucose, respectively, to G-3-P synthesis *in vivo*. Botion *et al.* (30) used a similar method but estimated glyceroneogenic flux by subtracting the rate of triglyceride glycerol synthesis obtained with $[U⁻¹⁴C]$ glucose from that obtained with $[^3H_2]$ O. Because a significant amount of [14C]glucose carbon is incorporated into G-3-P via [14C]lactate, such an approach will underestimate glyceroneogenesis. For this reason, Botion *et al.* (30) described their results as the *minimal* contribution of glyceroneogenesis to triglyceride glycerol formation. In this study we have quantified the direct contribution of glucose to triglyceride glycerol synthesis by subtracting from total glucose incorporation in triglyceride glycerol the estimated contribution of ${}^{14}C$ via lactate. Therefore, our data represent the "true" contribution of glucose to triglyceride glycerol. In addition, we confirmed the predominant role of glyceroneogenesis by examining the relative ratio of $\rm ^{14}C/^{3}H$ on C-1 and $(C-1 + C-3)$ of triglyceride glycerol (Table 3). These data suggest that the major sources of carbon in triglyceride glycerol are pyruvate, lactate, and alanine (or the carbon skeletons of any of other gluconeogenic amino acid) via glyceroneogenesis. The negative values for the contribution of glucose to triglyceride glycerol synthesis could be due to the following. First, we determined the $[14C]$ lactate SA after its isolation from the plasma. Although we are confident in the accuracy of our results, a small underestimation of the concentration of lactate could result in an overestimation of $[{}^{14}C]$ lactate SA. A higher $[{}^{14}C]$ lactate SA will result in an overestimation of the glyceroneogenic flux from $[14C]$ lactate. Second, the dilution factor (2.2) for the loss of label in the citric acid cycle was based on literature values for the liver (28); we could not find a similar estimate for the adipose tissue. We may have underestimated the dilution in the adipose tissue, as glyceroneogenic flux relative to citric acid cycle flux in this tissue is far less than gluconeogenic flux relative to citric acid cycle flux in the liver. The smaller dilution factor will result in overestimation of glyceroneogenesis from lactate. Third, we estimated the ${}^{3}H$ labeling of C-3 of glycerol from the total tritium labeling of triglyceride glycerol. This would result in an overestimation of label at C-3 and, therefore, an overestimation of glyceroneogenesis. For these reasons, we have elected to display both the total glucose incorporation into triglyceride glycerol and the estimated flux direct from glucose in Tables 2, 5, and 6. Because of the possible overestimation of glyceroneogenesis via lactate, the estimated contribution of glucose in the present study is "minimal."

Glyceroneogenesis in Adipose Tissue—We have quantified glyceroneogenesis in adipose tissue in response to fasting, sucrose supplementation, and intravenous infusion of epinephrine. Our data show that during fasting there was no change in the rate of glyceroneogenesis, as compared with controls, and the direct contribution of glucose to triglyceride glycerol was negligible. Fasting is associated with a lower expression of GLUT 4 (31, 32) and a decreased uptake and phosphorylation of 2-deoxyglucose by adipocytes *in vitro* (33). There was a 50% lower rate of glucose uptake by adipose tissue, as measured by arterio-venous difference (34) in rats that were fasted for 48 h. Experimental deletion of GLUT 4 in the adipose tissue of mice, although reducing glucose uptake, did not impact on the triglyceride mass (35). Because PEPCK-C activity increases in the adipose tissue of fasted rats (36), we anticipated that glyceroneogenesis would be increased after 48 h of starvation to provide G-3-P for TG-FA cycling. Although not measured, the TG-FA cycling may already be high in control animals (\sim 8 h fast), so that starvation for 48 h did not cause a further increase in TG-FA cycling and, therefore, no increase in glyceroneogenesis.

Both high carbohydrate feeding and intravenous glucose administration have been shown to increase the concentration of plasma insulin, increase glucose uptake by the adipose tissue, and promote lipogenesis (37-40). *In vivo* data using ²H₂O tracer showed that glucose was the predominant source of triglyceride glycerol in both visceral and epididymal adipose tissue in the mice fed a high carbohydrate diet for 75 days (41). Based upon these data, we expected glyceroneogenesis would be lower and the contribution of glucose higher in rats maintained on a sucrose-supplemented diet. The direct contribution of glucose to triglyceride glycerol synthesis was higher than controls in response to a sucrose supplemented diet (Table 2). Glyceroneogenesis also increased and remained the predominant pathway for triglyceride glycerol synthesis. In addition, a 90% increase in lipogenesis was observed in the adipose tissue. Wolfe and Peters (38) demonstrated that lipolysis continued to occur in humans when glucose was infused at 8 mg/kg/min and that the rate of appearance of fatty acids in plasma was significantly reduced due to enhanced intracellular TG-FA cycling. The observed increase in glyceroneogenesis in the sucrose supplemented animals in our study may support triglyceride glycerol synthesis for enhanced intracellular TG-FA cycling as well as the esterification of *de novo* synthesized fatty acids. Increased *de novo* lipogenesis in the adipose tissue was noted in the sucrose-fed rats in our study. It is possible that a fraction of the labeled fatty acids came from lipids that were synthesized in the liver as a consequence of sucrose feeding (39) and transported to the adipose tissue. The rate of lipogenesis has been shown to decrease markedly in the adipose tissue of rats with age (42, 43). Because we detected 14 C radioactivity in fatty acids isolated from plasma triglyceride of sucrose-supplemented animals, such a possibility cannot be excluded.

Our finding of a high rate of glyceroneogenesis in sucrose-fed animals is at variance with that of Chen *et al.* (41), who showed a lower fractional contribution of glyceroneogenesis and a higher contribution of glucose in mice fed a high carbohydrate diet for 75 days. These differences may be related to the short duration of our study, the specific difference in dietary regimen (*i.e.* high carbohydrate and low fat diet *versus* sucrose supplementation followed by glucose infusion in our study), and the tracer method employed. Chen *et al.* (41) suggested that their method was optimal for calculating the fractional rate of synthesis of triglyceride glycerol. In contrast, our technique was optimized for measuring quantitative rates of glyceroneogenic flux over a short period. In addition, the experimental approach

of Chen *et al.* (41), utilizing long term incorporation of label, represents a cumulative effect of feeding and fasting.

Response to Epinephrine Infusion—The effect of enhanced TG-FA cycling on glyceroneogenesis was examined by determining its response to epinephrine infusion. Epinephrine, a β -adrenergic agonist, increases TG-FA cycling in humans (44) and decreases glucose uptake by the adipose tissue (45). In addition, infusion of epinephrine causes an elevation in the concentration of lactate in the blood (46). Epinephrine infusion at 500 ng/kg/min for 3 h resulted in a high rate of glyceroneogenesis. There was no measurable contribution of glucose to triglyceride glycerol formation during epinephrine infusion. These data suggest that enhanced TG-FA cycling is associated with high rate of glyceroneogenesis.

As expected, PEPCK-C activity was higher in epididymal and mesenteric adipose depots from rats fasted for 48 h as compared with animals maintained on a high carbohydrate diet. However, the relative changes in the activity of PEPCK-C did not correlate with the measured rate of glyceroneogenesis. Glyceroneogenesis was highest in the adipose tissue of rats fed a sucrose supplemented diet, when PEPCK-C activity was at its lowest. Nevertheless, the PEPCK-C activity was always higher than the respective rate of glyceroneogenesis. High flux and low activity suggests that glyceroneogenic flux may be dependent on the provision of substrate (both pyruvate/lactate and fatty acids) or that PEPCK-C in adipose tissue is controlled by an allosteric regulator. The latter suggestion is interesting but unlikely, as no such compound has yet been identified that regulates this enzyme. It is possible that PEPCK-C plays additional roles other than supporting glyceroneogenesis in the adipose tissue and other tissues in which this pathway is active. For example, deletion of the gene for PEPCK-C in the liver resulted in a marked reduction of citric acid cycle flux (47), presumably due to an altered rate of cataplerosis in the tissue. This area clearly needs further study.

Glucose Uptake and Glyceroneogenesis by the Adipose Tissue— The key issues raised by our study are as follows. 1) Glucose uptake occurs in adipose tissue, but glucose carbon is not incorporated directly into G-3-P for triglyceride synthesis, and 2) high rate of glyceroneogenesis is evident in the presence of glucose uptake in this tissue. The simultaneous occurrence of glucose metabolism and glyceroneogenesis suggests either (*a*) intracellular compartmentation of G-3-P in two different, nonmixing pools, or (*b*) the existence of two different cell types in the adipose tissue, a predominantly glycolytic cell and a predominantly triglyceride storing cell in which glyceroneogenesis is dominant (Fig. 5).

Currently there are no data in the literature that support the existence of two separate functional pools of G-3-P, *i.e.* one for glycolysis and the other for glyceroneogenesis, in the adipose tissue. However, there are multiple examples of apparently non-mixing intracellular pools of biochemical intermediates in several different metabolic pathways, *e.g.* acyl-CoA, diacylglycerol, leucine (48–50).

Evidence of multiple cell types in the adipose tissue is well documented. In addition to adipocytes, it contains endothelial cells and macrophages that primarily metabolize glucose to lactate (51, 52). Furthermore, undifferentiated preadipocytes do

FIGURE 5. **The two compartment (or two cell-type) hypothesis.** Two different cell types exist within an adipose tissue depot; 1) undifferentiated adipocytes which do not synthesize triglyceride and are predominantly glycolytic (*left side*); 2) differentiated adipocytes which display the phenotype characteristic of mature adipocytes (namely a large triglyceride reservoir) and synthesize triglyceride (*right side*). The differentiated adipocytes may rely mostly on glyceroneogenesis for the deposition of triglyceride.

not deposit triglycerides and may be primarily glycolytic (53). Mature adipocytes are fully differentiated cells that exhibit an adipocyte-like phenotype, namely a large reservoir of triglyceride. In addition, PEPCK expression is a late event, occurring during terminal differentiation of the adipocyte (54). Smith (55) has proposed that mature adipocytes range from young to old and are insulin-sensitive to insulin-resistant, respectively. Our data are a composite of the contribution of glyceroneogenesis and glucose metabolism in all of the cells present in the adipose tissue. It is possible that the glycolytic cells metabolize glucose to lactate, which is then released into the interstitium where it is available as a glyceroneogenic substrate for the triglyceridestoring cells. Adipocytes express the gene for the monocarboxylate transporter-1, which may be responsible for both lactate release, as well as its uptake from the interstitium of adipose tissue (56).*In vivo* studies in healthy, lean humans using microdialysis techniques show that after an overnight fast the interstitial concentration of lactate is significantly higher in abdominal and femoral subcutaneous adipose tissue than in plasma, suggesting a local release of lactate (57). Furthermore*,* in response to an oral glucose load, both plasma and interstitial lactate levels increased in parallel; however, the interstitial lactate concentration was much higher than that in the plasma (57). Increased glucose metabolism, induced by overexpression of hepatic glucokinase in the adipose tissue of mice, resulted in higher glucose uptake and higher lactate production without an increase in triglyceride synthesis (58). Only future studies will confirm or refute these two hypotheses, *i.e.* functionally separate non-mixing pools of G-3-P or the two cell types of adipocytes.

Glyceroneogenesis in the Skeletal Muscle—Our data are the first demonstration of glyceroneogenesis in skeletal muscles. In response to fasting as well as sucrose feeding, glyceroneogenesis was the main contributor to triglyceride glycerol formation, whereas the direct contribution of glucose was not measurable. The low incorporation of glucose noted in this study may be due in part to the relatively small triglyceride pool in skeletal muscle; the intramyocellular triglyceride pool is typically a few μ mol/g of muscle (59). During fasting, glyceroneogenesis would be expected to provide the G-3-P for triglyceride glycerol synthesis, as insulin-mediated GLUT 4 translocation and glu-

cose uptake by the skeletal muscle is decreased (60). Furthermore, TG-FA cycling is active in the oxidative muscle of overnight-fasted rats (61). Although we anticipated that glyceroneogenesis would be a functional pathway, due to the presence of PEPCK-C activity in skeletal muscle (14), the dominance of this pathway was unexpected. Even more surprising was the lack of a direct contribution of glucose to G-3-P synthesis, given that in response to a glucose load, skeletal muscle is responsible for the majority $(\sim 85\%)$ of insulinmediated glucose uptake (62). Our data demonstrating a marginal contribution of glucose to triglyceride glycerol in skeletal muscle are consistent with the report of Guo and Jensen (15), who, using [6-³H]glucose as a tracer, did not observe incorporation of ³H in triglyceride glycerol. In contrast, when $[6-14)$ C glucose was employed, a significant amount (\sim 20%) of ¹⁴C incorporation in triglyceride glycerol was observed. Because ³H from glucose is lost to body water during the equilibration with pyruvate, the authors suggested that glucose carbon was incorporated into triglyceride glycerol via the indirect pathway (glyceroneogenesis).

Hepatic Glyceroneogenesis—The fractional contribution of gluconeogenesis to the glucose Ra changed as expected (about 30% lower in controls, which increased to $~60\%$ after a 48-h fast), whereas glyceroneogenesis remained constant at about $~\sim$ 60% under all conditions studied. Furthermore, glyceroneogenesis, and not glucose metabolism via glycolysis, was the dominant pathway for hepatic triglyceride glycerol synthesis, even in sucrose-fed, glucose-infused animals. This was surprising, as exogenous glucose infusion would be expected to increase hepatic glucose uptake, and glucose should then become the major source of G-3-P. The levels of exogenous glucose infusion may not have been high enough to increase hepatic glucose uptake to a point where glucose, via glycolysis, became the major source of G-3-P. If the rate of infusion of glucose were increased, a corresponding increase in glucose uptake and its subsequent conversion to triglyceride glycerol might have been observed. However, Kalhan *et al.* (18) did not observe any effect of high glucose and insulin infusion during a hyperinsulinemic clamp on the relative contribution of pyruvate or glucose to triglyceride glycerol in type 2 diabetic subjects.

The present study clearly demonstrates that glyceroneogenesis occurs in adipose tissue, skeletal muscle, and liver of rat. This pathway may play a significant role in the control of triglyceride turnover and be a potential target for the treatment of obesity and diabetes (63), emphasizing the importance of PEPCK-C in both carbohydrate and lipid metabolism. However, several fundamental metabolic questions concerning glyceroneogenesis need further study. The carbon source for the G-3-P in adipose tissue and skeletal muscle is not well understood. Lactate is clearly a major precursor of triglyceride glycerol via glyceroneogenesis, but others, such as alanine and the carbon skeletons of gluconeogenic amino acids that enter the citric acid cycle are also potential candidates (16). The source of the NADH for the synthesis of G-3-P is also not well established. Glyceroneogenesis requires two molecules of NADH in the cytosol for every molecule of G-3-P synthesized; one is required at the glyceraldehyde-3-phosphate dehydrogenase step and the other at G-3-P dehydrogenase. One molecule of NADH is produced via cytosolic NAD-malate dehydrogenase when malate is oxidized to oxaloacetate. The source of the other molecule of NADH is not clear for any intermediate other than lactate, which generates an additional reducing equivalent in the cytosol when it is oxidized to pyruvate via lactate dehydrogenase. It is possible that the malate-aspartate shuttle produces net cytosolic NADH, essentially bringing reducing equivalents from the mitochondria to the cytosol to support glyceroneogenesis or that dihydroxyacetone phosphate is reduced to G-3-P via the flavoprotein dehydrogenase in the inner mitochondrial membrane (*i.e.* a reversal of the G-3-P shuttle). In the latter case the electrons for the synthesis of NADH would be generated in the mitochondria by fatty acid oxidation. Both of the problems outlined above require further study before the metabolic regulation of glyceroneogenesis will be understood.

Acknowledgments—We thank Visvanathan Chandramouli, Parvin Hakimi, and Clarita Duenas for technical assistance in this study.

REFERENCES

- 1. Newsholme, E. A., and Crabtree, B. (1976) *Biochem. Soc. Symp.* 61–109
- 2. Reshef, L., Olswang, Y., Cassuto, H., Blum, B., Croniger, C. M., Kalhan, S. C., Tilghman, S. M., and Hanson, R. W. (2003) *J. Biol. Chem.* **278,** 30413–30416
- 3. Robinson, J., and Newsholme, E. A. (1967) *Biochem. J.* **104,** 2–4
- 4. Newsholme, E. A., and Taylor, K. (1969) *Biochem. J.* **112,** 465–474
- 5. Ballard, F. J., Hanson, R. W., and Leveille, G. A. (1967) *J. Biol. Chem.* **242,** 2746–2750
- 6. Reshef, L., Niv, J., and Shapiro, B. (1967) *J. Lipid Res.* **8,** 688–691
- 7. Olswang, Y., Cohen, H., Papo, O., Cassuto, H., Croniger, C. M., Hakimi, P., Tilghman, S. M., Hanson, R. W., and Reshef, L. (2002) *Proc. Natl. Acad. Sci. U. S. A.* **99,** 625–630
- 8. Franckhauser, S., Munoz, S., Pujol, A., Casellas, A., Riu, E., Otaegui, P., Su, B., and Bosch, F. (2002) *Diabetes* **51,** 624–630
- 9. Franckhauser, S., Munoz, S., Elias, I., Ferre, T., and Bosch, F. (2006) *Diabetes* **55,** 273–280
- 10. Chaves, V. E., Frasson, D., Martins-Santos, M. E., Boschini, R. P., Garofalo, M. A., Festuccia,W. T., Kettelhut, I. C., and Migliorini, R. H. (2006) *J. Nutr.* **136,** 2475–2480
- 11. Hanson, R. W., and Reshef, L. (1997) *Annu. Rev. Biochem.* **66,** 581–611
- 12. Goodpaster, B. H., He, J., Watkins, S., and Kelley, D. E. (2001) *J. Clin. Endocrinol. Metab.* **86,** 5755–5761
- 13. Krssak, M., Falk, P. K., Dresner, A., DiPietro, L., Vogel, S. M., Rothman, D. L., Roden, M., and Shulman, G. I. (1999) *Diabetologia* **42,** 113–116
- 14. Hakimi, P., Yang, J., Casadesus, G., Massillon, D., Tolentino-Silva, F., Nye, C. K., Cabrera, M. E., Hagen, D. R., Utter, C. B., Baghdy, Y., Johnson, D. H., Wilson, D. L., Kirwan, J. P., Kalhan, S. C., and Hanson, R. W. (2007) *J. Biol. Chem.* **282,** 32844–32855
- 15. Guo, Z., and Jensen, M. D. (1999) *J. Biol. Chem.* **274,** 23702–23706
- 16. Owen, O. E., Kalhan, S. C., and Hanson, R. W. (2002) *J. Biol. Chem.* **277,** 30409–30412
- 17. Kalhan, S. C., Mahajan, S., Burkett, E., Reshef, L., and Hanson, R.W. (2001) *J. Biol. Chem.* **276,** 12928–12931
- 18. Kalhan, S. C., Bugianesi, E., McCullough, A. J., Hanson, R. W., and Kelley, D. E. (2008) *Metabolism* **57,** 305–312
- 19. Folch, J., Lees, M., and Sloane Stanley, G. H. (1957) *J. Biol. Chem.* **226,** 497–509
- 20. Wieland, O. (1974) *Methods of Enzymatic Analysis*, Academic Press, Inc., London, 1404–1409
- 21. Gutmann, I., and Wahlefeld, A. W. (1974) *Methods of Enzymatic Analysis*, Academic Press, Inc., London, 1464–1472

- 22. Reeves, R. E. (1941) *J. Am. Chem. Soc.* **63,** 1476–1477
- 23. Bederman, I. R., Dufner, D. A., Alexander, J. C., and Previs, S. F. (2006) *Am. J. Physiol. Endocrinol. Metab.* **290,** E1048–E1056
- 24. Ballard, F. J., and Hanson, R. W. (1967) *Biochem. J.* **104,** 866–871
- 25. Steele, R.,Wall, J. S., De Bodo, R. C., and Altszuler, N. (1956)*Am. J. Physiol.* **187,** 15–24
- 26. Rognstad, R., Clark, D. G., and Katz, J. (1974) *Eur. J Biochem.* **47,** 383–388
- 27. Postle, A. D., and Bloxham, D. P. (1980) *Biochem. J.* **192,** 65–73
- 28. Hetenyi, G., Jr. (1982) *Fed. Proc.* **41,** 104–109
- 29. Katz, J., and Rognstad, R. (1966) *J. Biol. Chem.* **241,** 3600–3610
- 30. Botion, L. M., Brito, M. N., Brito, N. A., Brito, S. R., Kettelhut, I. C., and Migliorini, R. H. (1998) *Metabolism* **47,** 1217–1221
- 31. Berger, J., Biswas, C., Vicario, P. P., Strout, H. V., Saperstein, R., and Pilch, P. F. (1989) *Nature* **340,** 70–72
- 32. Ezaki, O. (1997) *Biochem. Biophys. Res. Commun.* **241,** 1–6
- 33. Bay, U., and Froesch, E. R. (1986) *Mol. Cell. Endocrinol.* **47,** 217–224
- 34. Kowalski, T. J., Wu, G., and Watford, M. (1997) *Am. J. Physiol.* **273,** E613–E622
- 35. Abel, E. D., Peroni, O., Kim, J. K., Kim, Y. B., Boss, O., Hadro, E., Minnemann, T., Shulman, G. I., and Kahn, B. B. (2001) *Nature* **409,** 729–733
- 36. Reshef, L., Meyuhas, O., Boshwitz, C., Hanson, R. W., and Ballard, F. J. (1972) *Isr. J. Med. Sci.* **8,** 372–381
- 37. Frayn, K. N., Shadid, S., Hamlani, R., Humphreys, S. M., Clark, M. L., Fielding, B. A., Boland, O., and Coppack, S. W. (1994) *Am. J. Physiol.* **266,** E308–E317
- 38. Wolfe, R. R., and Peters, E. J. (1987) *Am. J. Physiol.* **252,** E218–E223
- 39. Schwarz, J. M., Neese, R. A., Turner, S., Dare, D., and Hellerstein, M. K. (1995) *J. Clin. Investig.* **96,** 2735–2743
- 40. Kotani, K., Peroni, O. D., Minokoshi, Y., Boss, O., and Kahn, B. B. (2004) *J. Clin. Investig.* **114,** 1666–1675
- 41. Chen, J. L., Peacock, E., Samady, W., Turner, S. M., Neese, R. A., Hellerstein, M. K., and Murphy, E. J. (2005) *J. Biol. Chem.* **280,** 25396–25402
- 42. Karbowska, J., Kochan, Z., and Swierczynski, J. (2001) *Metabolism* **50,** 734–738
- 43. Shrago, E., Glennon, J. A., and Gordon, E. S. (1971) *Metabolism* **20,** 54–62
- 44. Wolfe, R. R., Peters, E. J., Klein, S., Holland, O. B., Rosenblatt, J., and Gary, H., Jr. (1987) *Am. J. Physiol.* **252,** E189-E196
- 45. Kashiwagi, A., Huecksteadt, T. P., and Foley, J. E. (1983) *J. Biol. Chem.* **258,**

13685–13692

- 46. Stainsby, W. N., Sumners, C., and Andrew, G. M. (1984) *J. Appl. Physiol.* **57,** 321–325
- 47. Burgess, S. C., Hausler, N., Merritt, M., Jeffrey, F. M., Storey, C., Milde, A., Koshy, S., Lindner, J., Magnuson, M. A., Malloy, C. R., and Sherry, A. D. (2004) *J. Biol. Chem.* **279,** 48941–48949
- 48. Carrasco, S., and Merida, I. (2004) *Mol. Biol. Cell* **15,** 2932–2942
- 49. Berge, R. K., Osmundsen, H., Aarsland, A., and Farstad, M. (1983) *Int. J. Biochem.* **15,** 205–209
- 50. Schneible, P. A., Airhart, J., and Low, R. B. (1981) *J. Biol. Chem.* **256,** 4888–4894
- 51. Newsholme, P., Curi, R., Gordon, S., and Newsholme, E. A. (1986) *Biochem. J.* **239,** 121–125
- 52. Newsholme, P., Gordon, S., and Newsholme, E. A. (1987) *Biochem. J.* **242,** 631–636
- 53. Tchkonia, T., Tchoukalova, Y. D., Giorgadze, N., Pirtskhalava, T., Karagiannides, I., Forse, R. A., Koo, A., Stevenson, M., Chinnappan, D., Cartwright, A., Jensen, M. D., and Kirkland, J. L. (2005) *Am. J. Physiol. Endocrinol. Metab.* **288,** E267–E277
- 54. Tontonoz, P., Hu, E., Devine, J., Beale, E. G., and Spiegelman, B. M. (1995) *Mol. Cell. Biol.* **15,** 351–357
- 55. Smith, S. A. (2003) *Biochimie* (*Paris*) **85,** 1219–1230
- 56. Bonen, A., Heynen, M., and Hatta, H. (2006) *Appl. Physiol. Nutr. Metab.* **31,** 31–39
- 57. Jansson, P. A., Larsson, A., Smith, U., and Lonnroth, P. (1994) *J. Clin. Investig.* **93,** 240–246
- 58. Franckhauser, S., Munoz, S., Hidalgo, A., Ferre, T., Mas, A., Elias, I., Cerdan, S., Pujol, A., and Bosch, F. (2007) *Diabetes* **56,** Suppl. 1, A458
- 59. Guo, Z., and Jensen, M. D. (1998) *J. Appl. Physiol.* **84,** 1674–1679
- 60. James, D. E., Brown, R., Navarro, J., and Pilch, P. F. (1988) *Nature* **333,** 183–185
- 61. Tagliaferro, A. R., Dobbin, S., Curi, R., Leighton, B., Meeker, L. D., and Newsholme, E. A. (1990) *Int. J. Obes.* **14,** 957–971
- 62. DeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., and Felber, J. P. (1981) *Diabetes* **30,** 1000–1007
- 63. Cadoudal, T., Fouque, F., Benelli, C., and Forest, C. (2008) *Med. Sci.* (*Paris*) **24,** 407–414

